http://www.exac.com daily 1 2007-12-11T15:24:27Z http://www.exac.com/news/exactech-announces-resolution-of-government-investigation GAINESVILLE, Fla. – December 7, 2010 – Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that it has entered into a Deferred Prosecution Agreement (DPA) with the United States Attorney's Office for the District of New Jersey (USAO) and a civil Settlement Agreement (CSA) with the United States. These agreements resolve the investigation commenced by the USAO in December 2007 into the Company's consulting arrangements with orthopaedic surgeons relating to its hip and knee products in the United States. Pursuant to the DPA, an independent monitor will review and evaluate the Company's compliance with its obligations under the DPA. The USAO specifically acknowledges in the DPA that it does not allege that the Company's conduct adversely affected patient health or patient care. No publisher lnorthsea Press Releases 2010-12-08T21:08:18Z News Item http://www.exac.com/news/exactech-q3-revenue-42.0m-eps-0.11-market-leading-extremity-growth-at-33 GAINESVILLE, Fla. – November 2, 2010 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $42.0 million for the third quarter of 2010, a 1% decrease from $42.4 million in the third quarter of 2009. Net income decreased 46% to $1.5 million, or $0.11 per diluted share, compared to $2.7 million, or $0.21 per diluted share, in the same quarter a year ago. Net income for the quarter, excluding pre-tax legal expenses and costs of $0.2 million related to the ongoing Department of Justice (DOJ) inquiry, was $1.6 million or $0.12 EPS. No publisher lnorthsea Press Releases 2010-11-02T20:29:51Z News Item http://www.exac.com/news/exactech-says-q3-financial-results-below-expectations GAINESVILLE, Fla. – October 18, 2010 – Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, said today the company’s financial results for the third quarter ended September 30, 2010 will be below the company’s previously announced guidance with estimated revenues for the third quarter of $42 million. The shortfall is due to greater than expected costs associated with entry into new markets and distribution channel changes internationally. In addition to the impact of these changes on revenue, the company said business in several markets was softer than originally expected. No publisher lnorthsea Press Releases 2010-10-18T20:40:20Z News Item http://www.exac.com/news/exactech-acquires-minimally-invasive-spine-reconstruction-portfolio GAINESVILLE, Fla. – August 27, 2010 – Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today the acquisition of several innovative spine product lines and all related technology from VertiFlex, Inc. a leading developer of minimally invasive and motion preserving spinal surgery technologies. No publisher lnorthsea Press Releases 2010-09-21T16:17:25Z News Item http://www.exac.com/news/exactech-to-present-at-upcoming-investor-conferences GAINESVILLE, Fla. – August 9, 2010 – Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced its schedule of participation at upcoming investor conferences: No publisher lnorthsea Press Releases 2010-08-09T17:34:42Z News Item http://www.exac.com/news/exactech-q2-revenue-up-10-net-income-up-14-eps-0.23 GAINESVILLE, Fla. – August 3, 2010 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $47.6 million for the second quarter of 2010, a 10% increase over $43.3 million in the second quarter of 2009. Net income increased 14% to $3.0 million, or $0.23 per diluted share, compared to $2.6 million, or $0.20 per diluted share, in the same quarter a year ago. Net income for the quarter, excluding pre-tax legal expenses and costs of $0.4 million related to the ongoing Department of Justice (DOJ) inquiry, was $3.2 million or $0.25 EPS. No publisher lnorthsea Press Releases 2010-08-03T21:04:09Z News Item http://www.exac.com/news/exactech-schedules-second-quarter-2010-earnings-release-and-conference-call GAINESVILLE, Fla. – July 16, 2010 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its second quarter 2010 financial results on August 3, 2010. A copy of the earnings release will be available at http://www.hawkassociates.com. No publisher lnorthsea Press Releases 2010-07-16T14:14:28Z News Item http://www.exac.com/news/exactech-to-present-at-the-2010-noble-financial-equity-conference-on-june-7 GAINESVILLE, Fla. – June 2, 2010 – Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will present at the Sixth Annual Noble Financial Equity Conference in Hollywood, Florida. The two-day investor conference will showcase 140 small cap public companies. No publisher lnorthsea Press Releases 2010-08-12T00:45:42Z News Item http://www.exac.com/news/exactech-acquires-key-supplier-secures-proprietary-knee-replacement-technology GAINESVILLE, Fla. – May 25, 2010 – Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that the company has acquired Brighton Partners, Inc., the sole source supplier of the direct compression molded polyethylene bearings used exclusively in Exactech’s flagship product, the Optetrak® knee replacement system. The acquisition includes the company’s assets, technology and know-how to continue manufacturing at the Sarasota, Fla.-based facility. Exactech plans to retain the Brighton Partners employees and to add additional staff as needed to support the company’s future growth. No publisher lnorthsea Press Releases 2010-05-25T14:12:22Z News Item http://www.exac.com/news/exactech-q1-revenue-up-13-net-income-up-33-reflecting-strong-surge-in-international-orthopaedic-sales-and-decreased-legal-costs GAINESVILLE, Fla. – April 27, 2010 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today revenue of $49.1 million for the first quarter of 2010, a 13% increase over $43.3 million in the first quarter of 2009. Net income was $3.3 million, or $0.25 per diluted share, compared to $2.5 million, or $0.19 per diluted share, in the same quarter a year ago. Net income for the quarter, excluding pre-tax legal expenses and costs of $0.2 million related to the ongoing Department of Justice (DOJ) inquiry, was $3.4 million or $0.26 EPS. No publisher lnorthsea Press Releases 2010-05-25T14:18:24Z News Item http://www.exac.com/news/exactech-approved-to-begin-marketing-novationae-hip-system-in-high-demand-asian-market Gainesville, Fla. – April 15, 2010 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that the company has been granted approval to market its Novation® primary hip replacement system in Japan, a robust orthopaedics market where hip replacement surgeries outnumber knee replacement procedures No publisher lnorthsea Press Releases 2010-04-15T16:59:58Z News Item http://www.exac.com/news/exactech-schedules-first-quarter-2010-earnings-release-and-conference-call GAINESVILLE, Fla. – April 13, 2010 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will release its first quarter 2010 financial results on Tuesday, April 27, 2010 after regular trading hours end. A copy of the earnings release will be available at http://www.hawkassociates.com. No publisher lnorthsea Press Releases 2010-04-13T14:18:33Z News Item http://www.exac.com/news/exactech-to-meet-with-financial-analysts-at-aaos-orthopaedic-meeting-present-growth-strategies-at-investor-conference GAINESVILLE, Fla. – March 8, 2010 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, today announced its schedule of upcoming investor events. No publisher lnorthsea Press Releases 2010-03-08T18:10:13Z News Item http://www.exac.com/news/exactech-platform-fracture-stem-for-shoulder-surgeries-receives-fda-clearance GAINESVILLE, Fla. – March 2, 2010 -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the company’s Equinoxe® Platform Fracture Stem, the latest addition to the company’s shoulder arthroplasty line. No publisher lnorthsea Press Releases 2010-03-02T19:13:52Z News Item http://www.exac.com/news/exactech-2009-revenue-up-10-to-177m GAINESVILLE, Fla. – February 22, 2010 -- Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, extremities, spine and biologic materials, announced today that revenue for 2009 increased 10% to $177.3 million from $161.7 million in 2008. Diluted earnings per share for the year was $0.65 based on net income of $8.3 million. This compares with net income of $11.1 million or $0.87 diluted EPS a year ago. Net income for 2009 included pre-tax legal expenses and estimated settlement costs of $7.0 million related to the ongoing Department of Justice (DOJ) inquiry. Excluding the impact of these legal expenses, 2009 net income was $13.2 million or $1.03 diluted EPS compared with $12.7 million or $0.99 diluted EPS in 2008. No publisher kmiranda Press Releases 2010-02-23T01:33:42Z News Item